We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.
- Authors
Sonego, Benedetta; Ibatici, Adalberto; Rivoli, Giulia; Angelucci, Emanuele; Sola, Simona; Massone, Cesare
- Abstract
In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs.
- Subjects
T-cell lymphoma; ALEMTUZUMAB; LYMPHOMAS; MYCOSIS fungoides; ATEZOLIZUMAB; HISTOPATHOLOGY
- Publication
Cells (2073-4409), 2023, Vol 12, Issue 22, p2656
- ISSN
2073-4409
- Publication type
Article
- DOI
10.3390/cells12222656